76 related articles for article (PubMed ID: 6887536)
1. [Differential sensitivities of human malignant lymphoma cell lines to anti-cancer drugs].
Morikawa K; Harada T
Rinsho Ketsueki; 1983 Apr; 24(4):355-62. PubMed ID: 6887536
[No Abstract] [Full Text] [Related]
2. Differential sensitivities of five rat hepatoma cell lines to anticancer drugs.
Barranco SC; Haenelt BR; Gee EL
Cancer Res; 1978 Mar; 38(3):656-60. PubMed ID: 75057
[TBL] [Abstract][Full Text] [Related]
3. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
4. [Differential cell growth inhibition and terminal differentiation induction by chemotherapeutic agents of a human acute myelogenous leukemia cell line (HL-60) in vitro].
Himori T; Ohnuma T; Wakui A
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1605-11. PubMed ID: 6591856
[TBL] [Abstract][Full Text] [Related]
5. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
6. Effects of cytosine arabinoside, daunomycin, mithramycin, azacytidine, adriamycin, and camptothecin on mammalian cell cycle traverse.
Tobey RA
Cancer Res; 1972 Dec; 32(12):2720-5. PubMed ID: 4118765
[No Abstract] [Full Text] [Related]
7. Cell-kill kinetics of several S-phase-specific drugs.
Bhuyan BK; Fraser TJ; Gray LG; Kuentzel SL; Neil GL
Cancer Res; 1973 Apr; 33(4):888-94. PubMed ID: 4735241
[No Abstract] [Full Text] [Related]
8. Glutamate and antimitotic agents induce differentiation, p53 activation, and apoptosis in rodent neostriatal cell lines immortalized with the tsA58 allele of SV40 large T antigen.
Conejero C; Wright R; Freed W
Exp Neurol; 1999 Jul; 158(1):109-20. PubMed ID: 10448422
[TBL] [Abstract][Full Text] [Related]
9. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
[TBL] [Abstract][Full Text] [Related]
10. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
11. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
12. Quantitative description of morphologic changes effected by antileukemic agents in L1210 leukemia cells.
Iwasaki H; Liu YP; Nojyo Y; Ueda T; Nakamura T
Anticancer Res; 1995; 15(1):133-9. PubMed ID: 7733623
[TBL] [Abstract][Full Text] [Related]
13. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
Tardi P; Johnstone S; Harasym N; Xie S; Harasym T; Zisman N; Harvie P; Bermudes D; Mayer L
Leuk Res; 2009 Jan; 33(1):129-39. PubMed ID: 18676016
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelium: target or victim of cytostatic therapy?
Romanov YA; Chervontseva AM; Savchenko VG; Smirnov VN
Can J Physiol Pharmacol; 2007; 85(3-4):396-403. PubMed ID: 17612648
[TBL] [Abstract][Full Text] [Related]
15. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitivity of drug-sensitive and drug-resistant P388 leukemia cell lines after hyperthermic treatment.
Toffoli G; Bevilacqua C; Franceschin A; Boiocchi M
J Chemother; 1989 Jul; 1(4 Suppl):1159-61. PubMed ID: 16312815
[No Abstract] [Full Text] [Related]
17. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
18. Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2).
Fic M; Podhorska-Okolow M; Dziegiel P; Gebarowska E; Wysocka T; Drag-Zalesinska M; Zabel M
In Vivo; 2007; 21(3):513-8. PubMed ID: 17591362
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent survival and cell-cycle progression of cultured cells exposed to chemotherapeutic drugs.
Drewinko B; Barlogie B
Cancer Treat Rep; 1976 Dec; 60(12):1707-17. PubMed ID: 1026329
[No Abstract] [Full Text] [Related]
20. Duration of the dormant state in an established cell line of human hematopoietic cells.
Clarkson BD; Fried J; Chou TC; Strife A; Ferguson R; Sullivan S; Kitahara T; Oyama A
Cancer Res; 1977 Dec; 37(12):4506-22. PubMed ID: 336195
[No Abstract] [Full Text] [Related]
[Next] [New Search]
